Pentax Medical
Pentax Medical, a division of Hoya Corporation, is a leading provider of innovative medical imaging solutions, headquartered in Japan. Established in 1919, the company has a rich history of advancements in endoscopy and minimally invasive surgical technologies, serving healthcare professionals across the globe, particularly in Europe, Asia, and North America. Specialising in endoscopic equipment, Pentax Medical offers a range of products, including high-definition endoscopes and imaging systems that enhance diagnostic accuracy and patient outcomes. Their commitment to quality and innovation has positioned them as a trusted partner in the medical community, with notable achievements in developing user-friendly devices that prioritise patient safety and comfort. With a strong market presence, Pentax Medical continues to lead the way in transforming healthcare through cutting-edge technology.
DitchCarbon Score
How does Pentax Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pentax Medical's score of 39 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pentax Medical's reported carbon emissions
In 2023, Pentax Medical reported total carbon emissions of approximately 866,000 kg CO2e, a decrease from about 886,000 kg CO2e in 2022. The emissions breakdown includes 52,000 kg CO2e from Scope 1, 29,000 kg CO2e from Scope 2, and 785,000 kg CO2e from Scope 3 emissions. This trend indicates a commitment to reducing their carbon footprint over time. Looking ahead, Pentax Medical aims to further decrease their emissions, with projected total emissions of about 788,000 kg CO2e for 2025. The company has maintained consistent Scope 1 and Scope 2 emissions figures, while focusing on reducing Scope 3 emissions, which constitute the majority of their carbon output. Despite the absence of specific reduction targets or climate pledges, Pentax Medical's ongoing efforts to lower emissions reflect a broader commitment to sustainability and climate responsibility within the medical technology industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2025 | |
|---|---|---|---|
| Scope 1 | 52,000 | 00,000 | 00,000 |
| Scope 2 | 29,000 | 00,000 | 00,000 |
| Scope 3 | 804,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pentax Medical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
